Last update June 10, 2018
Very Low Risk
A methylxanthine with peripheral vasodilatory properties, reduction of blood viscosity and platelet antiaggregant, improving blood flow. It also inhibits the production of TNFα cytokine.
Indicated in chronic peripheral vascular obstruction of limbs. It has been used experimentally in maternal peripartum cardiomyopathy (Garg 2015), in sepsis, including neonatal (Tarnow 2010) and in necrotizing enterocolitis (Patole 2007).
Administered orally 3 times a day
It is excreted in breast milk in clinically negligible amounts (Witter 1985).
Possible side effects are not frequent.
When breastmilk freezes at -15º, pentoxifylline remains stable for 3 weeks (Bauza 1984).
There are very few bibliographical references. It is classified as having low therapeutic efficacy (Canary Islands Health Service 2011, INSALUD 2001).
We do not have alternatives for Pentoxifylline since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.